Related Experiment Videos
[A decrease in left ventricular hypertrophy and the dynamics of the parameters of circadian BP monitoring under the
Insights
Ramipril, an angiotensin-converting enzyme inhibitor, effectively reduces left ventricular hypertrophy (LVH) in hypertensive patients. This beneficial effect on cardiac structure occurs independently of its blood pressure-lowering action.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Left ventricular hypertrophy (LVH) is a significant risk factor in patients with essential hypertension.
- Angiotensin-converting enzyme (ACE) inhibitors are commonly used to manage hypertension.
- Understanding the specific mechanisms by which ACE inhibitors affect LVH is crucial for optimizing treatment strategies.
Purpose of the Study:
- To investigate the factors influencing the action of ramipril, an ACE inhibitor, in reducing left ventricular hypertrophy (LVH).
- To determine if ramipril's effect on LVH is independent of its blood pressure-lowering capabilities.
Main Methods:
- Echocardiography (echo-CG) was used to measure left ventricular mass in 45 patients with mild to moderate essential hypertension and LVH.
- Twenty-four-hour ambulatory arterial pressure (AP) monitoring was conducted.
- Multiple regression analysis examined the prognostic significance of various parameters including age, sex, body mass, disease duration, mean 24-h AP, AP variability, and nocturnal fall.
Main Results:
- Ramipril demonstrated a significant reduction in left ventricular hypertrophy (LVH).
- The observed decrease in LVH was independent of the drug's effect on lowering arterial pressure.
- Key prognostic factors influencing ramipril's action were analyzed through multiple regression.
Conclusions:
- Ramipril effectively reduces left ventricular hypertrophy (LVH) in patients with essential hypertension.
- The beneficial impact of ramipril on cardiac remodeling is not solely mediated by its antihypertensive effects.
- Further research can explore the direct cellular mechanisms of ramipril on cardiac tissue.
Abstract:
To evaluate factors of action of ramipril, an inhibitor of angiotensin-converting enzyme, which may induce a decrease in left ventricular hypertrophy (LVH), 45 LVH patients aged 21-53 years with mild and moderate essential hypertension have underwent echo-CG determination of left ventricular mass and 24-h monitoring of arterial pressure (AP). Multiple regression was used to examine prognostic significance of such parameters as age, sex, height, weight, duration of the disease, mean 24-h AP, its variability and the degree of nocturnal fall. It was found that ramipril reduced LVH irrespective of the hypotensive effect.